The stock of Novavax, Inc (NASDAQ:NVAX) last traded at $6.42, down -4.25% from the previous session.
NVAX stock price is now -10.50% away from the 50-day moving average and -34.71% away from the 200-day moving average. The market capitalization of the company currently stands at $1.03B.
With the price target of $19, BTIG Research recently initiated with Buy rating for Novavax, Inc (NASDAQ: NVAX). On July 30, 2024, JP Morgan Downgraded its previous ‘Neutral’ rating to ‘Underweight’ on the stock keeping its target price maintained at $8, while ‘BofA Securities’ rates the stock as ‘Neutral’
In other news, YOUNG JAMES F, Former Director bought 4,000 shares of the company’s stock on Apr 14 ’25. The stock was bought for $24,406 at an average price of $6.10. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 13 ’24, Director King Rachel K. sold 4,150 shares of the business’s stock. A total of $37,435 was realized by selling the stock at an average price of $9.02. This leaves the insider owning 14,770 shares of the company worth $94823.4. A total of 8.87% of the company’s stock is owned by insiders.
During the past 12 months, Novavax, Inc has had a low of $4.10 and a high of $23.86. The fifty day moving average price for NVAX is $7.1732 and a two-hundred day moving average price translates $9.83355 for the stock.
The latest earnings results from Novavax, Inc (NASDAQ: NVAX) was released for 2024-12-31. The company reported revenue of $88.31 million for the quarter, compared to $291.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -69.69 percent.
